As of 2025-07-15, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,610.32 mil USD. RARE's TTM EBITDA according to its financial statements is -540.93 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 13.4x | 12.9x |
| Forward P/E multiples | 20.6x - 43.4x | 32.0x |
| Fair Price | (86.16) - (55.70) | (93.98) |
| Upside | -394.8% - -290.5% | -421.5% |
| Date | EV/EBITDA |
| 2025-07-14 | -6.67 |
| 2025-07-11 | -6.74 |
| 2025-07-10 | -7.10 |
| 2025-07-09 | -9.56 |
| 2025-07-08 | -9.08 |
| 2025-07-07 | -9.13 |
| 2025-07-03 | -9.20 |
| 2025-07-02 | -9.09 |
| 2025-07-01 | -8.34 |
| 2025-06-30 | -8.36 |
| 2025-06-27 | -8.40 |
| 2025-06-26 | -8.54 |
| 2025-06-25 | -8.61 |
| 2025-06-24 | -8.55 |
| 2025-06-23 | -8.47 |
| 2025-06-20 | -8.54 |
| 2025-06-18 | -8.59 |
| 2025-06-17 | -8.43 |
| 2025-06-16 | -8.54 |
| 2025-06-13 | -8.63 |
| 2025-06-12 | -9.05 |
| 2025-06-11 | -8.63 |
| 2025-06-10 | -8.63 |
| 2025-06-09 | -8.52 |
| 2025-06-06 | -8.55 |
| 2025-06-05 | -8.49 |
| 2025-06-04 | -8.42 |
| 2025-06-03 | -8.37 |
| 2025-06-02 | -8.31 |
| 2025-05-30 | -7.81 |
| 2025-05-29 | -8.05 |
| 2025-05-28 | -7.88 |
| 2025-05-27 | -8.06 |
| 2025-05-23 | -8.19 |
| 2025-05-22 | -8.16 |
| 2025-05-21 | -8.14 |
| 2025-05-20 | -8.59 |
| 2025-05-19 | -8.32 |
| 2025-05-16 | -8.18 |
| 2025-05-15 | -8.00 |
| 2025-05-14 | -7.97 |
| 2025-05-13 | -8.13 |
| 2025-05-12 | -8.30 |
| 2025-05-09 | -8.06 |
| 2025-05-08 | -8.27 |
| 2025-05-07 | -7.66 |
| 2025-05-06 | -8.05 |
| 2025-05-05 | -8.95 |
| 2025-05-02 | -9.05 |
| 2025-05-01 | -8.98 |